Epinephrine Shortage: What Providers and Prescribers Need to Know in 2026

Epinephrine auto-injectors remain one of the most essential — and most frustrating — prescriptions in allergy and emergency medicine. Despite improvements since the severe 2018–2019 shortage, providers continue to field calls from patients unable to fill their epinephrine prescriptions. This briefing covers the current supply landscape, prescribing strategies to improve patient access, cost barrier tools, and resources to help your practice stay ahead of the problem.

Current Supply Landscape: Where Things Stand in 2026

The epinephrine auto-injector market has stabilized considerably since the crisis years, but 'stabilized' does not mean 'reliable.' Key facts for 2026:

Multiple products are now FDA-approved and marketed: EpiPen and authorized generic, Auvi-Q (0.1/0.15/0.3 mg), Adrenaclick and generics, Symjepi, and neffy (nasal spray, approved August 2024).

Regional disparities persist. Availability varies significantly by geography and by pharmacy. Patients in rural areas or those locked into a single-pharmacy plan may have fewer options.

Seasonal demand spikes remain predictable. The August–September back-to-school surge stresses pharmacy inventory every year, and 2026 is not expected to be different.

The ASHP drug shortage database continues to list certain epinephrine injection formulations — particularly hospital-use prefilled syringes — as in shortage.

Prescribing Strategy: Write Device-Agnostic Prescriptions When Possible

One of the most practical steps prescribers can take is writing prescriptions for 'epinephrine auto-injector' rather than specifying 'EpiPen' or another brand. This gives pharmacists flexibility to dispense whichever product is in stock — whether that's the EpiPen authorized generic, Adrenaclick, or another FDA-approved device.

However, be aware that state substitution laws vary. In some states, pharmacists cannot substitute between different auto-injector devices (e.g., EpiPen to Adrenaclick) without a new prescription, even if the active ingredient is identical. Writing a device-agnostic prescription can preempt this barrier.

Dosing Guidance: When to Choose Which Product

Current guidelines recommend dosing based on patient weight:

Less than 7.5 kg: Use manual epinephrine injection (auto-injectors are not indicated at this weight)

7.5 kg to <15 kg: Auvi-Q 0.1 mg (the only auto-injector approved for this weight range)

15 kg to <30 kg: EpiPen Jr 0.15 mg, Auvi-Q 0.15 mg, or Adrenaclick 0.15 mg

30 kg or more: EpiPen 0.3 mg, Auvi-Q 0.3 mg, Adrenaclick 0.3 mg, or Symjepi 0.3 mg

Current guidelines recommend prescribing at least two auto-injectors per patient (the standard 2-pack), with consideration for additional sets for school, workplace, or travel. For patients with a history of biphasic reactions or those who live far from emergency services, additional doses may be warranted. A second dose is needed in 16–35% of anaphylaxis episodes.

Patient Cost Barriers: What Prescribers Should Know

Cost is a major barrier for many patients — surveys show that 43.6% of patients report high cost as a barrier to obtaining epinephrine auto-injectors. As a prescriber, knowing your options can help:

Auvi-Q $0 copay program (Kaléo): Commercially insured patients pay $0 through this program. It's one of the most generous savings programs in the category.

EpiPen Savings Card (Viatris): Reduces copay to as low as $0–$25 per prescription for commercially insured patients, for up to 6 auto-injectors per calendar year.

Viatris Patient Assistance Program: Provides free EpiPen to eligible uninsured or underinsured patients meeting income criteria.

Authorized generic: Prescribing or allowing substitution to the Viatris authorized generic (same device as EpiPen) can reduce cash cost by 40–50%.

State price caps: Several states (including Colorado since 2024, Illinois since 2025, and New York starting 2026) have enacted laws capping out-of-pocket costs for epinephrine auto-injectors, typically at $60–$100 for a 2-pack.

Device Training: A Critical and Often Missed Step

When patients switch between devices due to availability issues, they may be unfamiliar with the new device's activation mechanism. EpiPen, Auvi-Q, and Adrenaclick all work differently. When prescribing or renewing any epinephrine auto-injector, take a moment to review the patient's device technique — especially if they may receive a different product than they're accustomed to. Trainer devices are included in each auto-injector carton and should be used.

Tools for Providers: Helping Patients Find In-Stock Pharmacies

When patients call your office reporting that their prescription cannot be filled, it disrupts your workflow and their care. medfinder for providers offers a solution: medfinder calls pharmacies near the patient to identify which ones have the medication in stock. This takes the burden of pharmacy location off both your staff and your patient.

Additional resources for prescribers:

FDA Drug Shortage Database: Monitor current and resolved shortages for epinephrine auto-injectors at fda.gov/drugs/drug-shortages

ASHP Drug Shortage Database: More detailed clinical information on shortage status and alternatives at ashp.org

Allergy action plan templates: Ensure plans reference the generic medication name and include instructions for multiple device types

Key Takeaways for Prescribers

Write device-agnostic prescriptions when possible to allow pharmacist substitution

Know which devices are appropriate by patient weight, especially the Auvi-Q 0.1 mg for children under 15 kg

Brief patients on manufacturer savings programs at every renewal to reduce cost-driven non-adherence

Verify device technique whenever a patient switches products

Refer patients to medfinder when they report difficulty filling prescriptions

For a step-by-step guide to helping patients navigate availability issues, see our provider's guide to helping patients find epinephrine in stock.